Completed OBSERVATIONAL NCT00998309

Zithromax-SR 2g, Special Investigation (Regulatory Post Marketing Commitment Plan)

Zithromax-SR 2g, Special Investigation For Skin And Soft Tissue Infection, Sexually-Transmitted Infection, And Infection Of The Oral (Regulatory Post Marketing Commitment Plan)

Sponsor: Pfizer

Conditions Bacterial Infections

Interventions Azithromycin SR

Updated 8 times since 2017 Last updated: Apr 2, 2012 Started: Oct 31, 2009 Primary completion: Jan 31, 2011 Completion: Jan 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00998309, this observational or N/A phase trial focuses on Bacterial Infections and remains completed. Sponsored by Pfizer, it has been updated 8 times since 2009, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Study Description(click to expand)

All the patients whom an investigator prescribes the first Azithromycin SR should be registered within 14 days.

Status Flow

Change History

8 versions recorded

Jan 2026 — Present [monthly]

Completed
Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed

▶ Show 3 earlier versions

Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None
Feb 2017 — Apr 2018 [monthly]

Completed NA
Jan 2017 — Feb 2017 [monthly]

Completed NA

First recorded

Oct 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.